Plantigens: best prospect for defeating Malaria?
17 October, 2005 by Graeme O'NeillAustralian malaria vaccine researcher Professor Ross Coppell says smallpox was eradicated from the planet because the mass vaccination campaign employed a powdered formulation of dried, attenuated virus.
Norwood to commence phase II cancer vaccine trial
13 October, 2005 by Helen SchullerMelbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed an agreement for a phase II collaboration with the University of Texas MD Anderson Cancer Centre of Houston to determine whether its investigational melanoma cancer vaccine generates an enhanced immune response.
Prozac prevents onset of Huntington's disease in mice
13 October, 2005 by Graeme O'NeillA collaborative study by Australian and UK neuroscientists has shown that the anti-depressant fluoxetine (Prozac) prevents the onset of Huntington's disease (HD) in transgenic HD mice.
Avantogen cancer gene test partnership progressing
10 October, 2005 by Ruth BeranA partnership initiated in 2003 between Avantogen (ASX:ACU) (formerly Australian Cancer Technology) and Prof Ursula Kees at Perth's Telethon Institute for Child Health Research is closer to developing a diagnostic test to enable more effective treatment of cancer.
Prima Biomed sells anti-inflammatory program
06 October, 2005 by Helen SchullerPrima Biomed (ASX: PRR) has entered into an agreement to sell all the assets of its subsidiary Arthron to Toronto-based private company Trillium Therapeutics.
Antisense 'proof-of-concept' study demonstrates activity of ATL1101 in psoriasis patients
05 October, 2005 by Helen SchullerAntisense Therapeutics (ASX:ANP) has produced positive results from a 'proof-of-concept' study of its second generation antisense drug ATL1101 to suppress the insulin-like growth factor-1 receptor (IGF-1R), which is under development as a cream for the topical treatment of the skin disorder psoriasis.
Citrofresh quashes HIV orange cure talk
29 September, 2005 by Staff WritersGeelong-based disinfectant maker Citrofresh International (ASX:CTF), which caused a stock frenzy with news of a cure-all ingredient found in oranges, has dashed investors' hopes it had a vaccine against HIV, SARS, flu and the common cold.
Acrux granted four US patents, licensee meets with FDA
27 September, 2005 by Ruth BeranAcrux (ASX:ACR) has been granted four more US patents relating to its transdermal drug delivery technology.
Phosphagenics claims promising insulin results
21 September, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has successfully delivered insulin through the skin of animals using its patented transdermal drug delivery system TPM-01.
Psiron puts back cancer trial results
20 September, 2005 by Graeme O'NeillSydney oncology therapy developer Psiron (ASX:PSX) has announced a delay in reporting the results of its first phase I clinical trial of its cancer-slaying CVA 21 viral therapy in melanoma patients because of delays in access to supplies of the virus.
Russian approval granted for Norwood EyeCare products
16 September, 2005 by Helen SchullerNorwood Devices, a division of medical technologies group Norwood Abbey (ASX:NAL) has received approval from the Russian Ministry of Health to import and sell the Norwood EyeCare Epi-LASIK system.
SSH aims to raise $4.3m for Bio-Layer
16 September, 2005 by Ruth BeranSydney-based SSH Medical (ASX:SSH) has started accepting applications for subscriptions to raise approximately $4.3 million to provide working capital for material science company Bio-Layer, which SSH is acquiring.
First enrolment for Pharmaxis Aridol COPD study
16 September, 2005 by Helen SchullerDrug developer Pharmaxis (ASX:PXS) has enrolled its first patient for the phase II clinical trial to assess the ability of Aridol to predict the usefulness of inhaled corticosteroids as a treatment of chronic obstructive pulmonary disease (COPD).
Novogen drug reduces cardiovascular risk, subsidiary to list on NASDAQ
14 September, 2005 by Ruth BeranBiopharmaceutical company Novogen's (ASX:NRT) cardiovascular drug trans NV-04 has shown a significant reduction in blood pressure and reduced arterial stiffness in a Phase Ib clinical trial.
Grunt work over, Starpharma looks to VivaGel future
09 September, 2005 by Helen SchullerContinuing development of its lead product VivaGel has boosted Starpharma's (ASX:SPL) 2004-05 losses to $5.5 million, up 38 per cent from the previous year.
